Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Theravance Biopharma (TBPH) Depreciation & Amortization (CF): 2013-2025

Historic Depreciation & Amortization (CF) for Theravance Biopharma (TBPH) over the last 13 years, with Sep 2025 value amounting to $405,000.

  • Theravance Biopharma's Depreciation & Amortization (CF) fell 5.59% to $405,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $1.6 million, marking a year-over-year decrease of 1.85%. This contributed to the annual value of $1.7 million for FY2024, which is 14.54% down from last year.
  • Theravance Biopharma's Depreciation & Amortization (CF) amounted to $405,000 in Q3 2025, which was down 0.98% from $409,000 recorded in Q2 2025.
  • Over the past 5 years, Theravance Biopharma's Depreciation & Amortization (CF) peaked at $1.6 million during Q3 2021, and registered a low of $251,000 during Q4 2021.
  • For the 3-year period, Theravance Biopharma's Depreciation & Amortization (CF) averaged around $448,909, with its median value being $427,000 (2024).
  • As far as peak fluctuations go, Theravance Biopharma's Depreciation & Amortization (CF) surged by 162.55% in 2022, and later slumped by 61.01% in 2023.
  • Quarterly analysis of 5 years shows Theravance Biopharma's Depreciation & Amortization (CF) stood at $251,000 in 2021, then spiked by 162.55% to $659,000 in 2022, then slumped by 40.52% to $392,000 in 2023, then rose by 7.65% to $422,000 in 2024, then declined by 5.59% to $405,000 in 2025.
  • Its Depreciation & Amortization (CF) was $405,000 in Q3 2025, compared to $409,000 in Q2 2025 and $413,000 in Q1 2025.